Results 171 to 180 of about 26,040 (266)

Data‐driven thresholds for standardized classification of severe Alzheimer's disease neuropathology using digital neuropathology

Brain Pathology, EarlyView.
We generated digital pathologic algorithms (AI‐based modules that can be freely shared) to: optimize the sampling (ROI) for diagnosis of ADNC‐related tau pathology; compare/transition between Aperio and HALO platforms; and rationalize severe Braak NFT staging, so that all Braak‐VI cases had dementia, and all Braak‐V cases had MCI or dementia.
Ryan K. Shahidehpour, Allison M. Neltner, Mitchell A. Klusty, Cole Corbett, Angelique D. Gonzalez, David A. Gutman, David W. Fardo, Adam D. Bachstetter, Cody Bumgardner, Margaret E. Flanagan, Peter T. Nelson   +10 more
wiley   +1 more source

Apolipoprotein(a).

Nosotchu, 1999
openaire   +2 more sources

Does Walnut Supplementation Have Favourable Effect Apolipoprotein A, B and Blood Pressure? A Systematic Review, Meta-Analysis and Meta-Evidence of Randomised Clinical Trials. [PDF]

Endocrinol Diabetes Metab
Musazadeh V, Mahmoudinezhad M, Hosseini-Roknabadi SM, Falahatzadeh M, Shidfar F.   +4 more
europepmc   +1 more source

Clinicopathological and molecular heterogeneity of amyloid‐β in unnatural deaths under 70 years: A forensic autopsy–based study

Brain Pathology, EarlyView.
This study investigates amyloid‐beta (Aβ) pathology in a forensic autopsy cohort of relatively young individuals (40–69 years). Using detailed immunohistochemical analyses of multiple Aβ species, we demonstrate marked regional and molecular heterogeneity, particularly within the striatum.
Shojiro Ichimata, Yukiko Hata, Koji Yoshida, Ryo Tanaka, Shigeo Murayama   +4 more
wiley   +1 more source

SAA4: An Underdog Within the Serum Amyloid a Superfamily? [PDF]

Int J Mol Sci
Malle E, Madreiter-Sokolowski C, Windpassinger C.   +2 more
europepmc   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Apolipoprotein M: Structural insights, functional roles, and therapeutic approaches in vascular disease. [PDF]

J Biol Chem
Dorweiler TF, Hla T.
europepmc   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

British Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral, Nicholas Monaco, Daniel I. Brierley, Monica Imbernon   +3 more
wiley   +1 more source

A Robust Serum Proteomic Signature of the E2 Allele of Apolipoprotein E. [PDF]

Adv Sci (Weinh)
Sebastiani P, Reed E, Chandler KB, Lopez P, Lords H, Bae H, Costello CE, Au M, Deng LL, Li M, Xiang Q, Noh H, Pflieger L, Funk C, Rappaport N, Nygaard M, Short MI, Brent M, Monti S, Andersen SL, Perls TT.   +20 more
europepmc   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source